Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

by Venugopal, Balaji , Quinn, David I , Gross-Goupil, Marine , Mahave, Mauricio , Sawrycki, Piotr , Melichar, Bohuslav , Kopyltsov, Evgeniy , Sarwar, Naveed , Choueiri, Toni K , Burke, John M , Gurney, Howard , Bedke, Jens , Powles, Thomas , Lee, Jae Lyun , Alva, Ajjai , Hammers, Hans , Kitamura, Hiroshi , Hajek, Jaroslav , Perini, Rodolfo F , Haas, Naomi B , Chang, Yen-Hwa , Doshi, Gurjyot , Zhang, Pingye , Park, Se Hoon , Tomczak, Piotr , Willemann-Rogerio, Jaqueline , Ferguson, Thomas , Chevreau, Christine , Thiery-Vuillemin, Antoine , Topart, Delphine , Symeonides, Stefan N , Oudard, Stephane , Imai, Kentaro

in Adjuvants / Adult / Adverse events / Aged / Aged, 80 and over / Antibodies, Monoclonal, Humanized - adverse effects / Antibodies, Monoclonal, Humanized - therapeutic use / Antineoplastic Agents, Immunological - adverse effects / Antineoplastic Agents, Immunological - therapeutic use / Cancer / Carcinoma, Renal Cell - drug therapy / Carcinoma, Renal Cell - mortality / Carcinoma, Renal Cell - surgery / Chemotherapy, Adjuvant - adverse effects / Disease-Free Survival / Double-Blind Method / Female / Hematology / Humans / Immunotherapy / Intention to Treat Analysis / Kidney cancer / Kidney Neoplasms - drug therapy / Kidney Neoplasms - mortality / Kidney Neoplasms - surgery / Male / Metastasis / Middle Aged / Monoclonal antibodies / Nephrectomy / Nephrology / Nephrology General / Oncology / Patients / Pembrolizumab / Placebos / Recurrence / Renal cell carcinoma / Surgery / Survival Analysis / Targeted cancer therapy / Treatments in Oncology

2021

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

2021

Confirm

Do you wish to request the book?

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

2021

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Venugopal, Balaji,

Quinn, David I,

Gross-Goupil, Marine,

Mahave, Mauricio,

Sawrycki, Piotr,

Melichar, Bohuslav,

Kopyltsov, Evgeniy,

Sarwar, Naveed,

Choueiri, Toni K,

Burke, John M,

Gurney, Howard,

Bedke, Jens,

Powles, Thomas,

Lee, Jae Lyun,

Alva, Ajjai,

Hammers, Hans,

Kitamura, Hiroshi,

Hajek, Jaroslav,

Perini, Rodolfo F,

Haas, Naomi B,

Chang, Yen-Hwa,

Doshi, Gurjyot,

Zhang, Pingye,

Park, Se Hoon,

Tomczak, Piotr,

Willemann-Rogerio, Jaqueline,

Ferguson, Thomas,

Chevreau, Christine,

Thiery-Vuillemin, Antoine,

Topart, Delphine,

Symeonides, Stefan N,

Oudard, Stephane,

Imai, Kentaro

2021

Overview

In a double-blind, randomized trial involving nearly 1000 patients followed for a median of 2 years, pembrolizumab injections for 1 year after surgery led to improved disease-free survival at 24 months as compared with placebo (77% vs. 68%). Almost one third of patients in the pembrolizumab group had a grade 3 adverse event, but no deaths were due to pembrolizumab.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adjuvants

/ Adult

/ Adverse events

/ Aged

/ Aged, 80 and over

/ Antibodies, Monoclonal, Humanized - adverse effects

/ Antibodies, Monoclonal, Humanized - therapeutic use